title: [Clinical features and survival analysis of patients with CD56 expression in de- novo acute myeloid leukemia with t（8;21）].
abstract: OBJECTIVE
  To explore the clinical features and survival of patients with CD56 expression in de- novo acute myeloid leukemia（AML）with t（8;21). .
  
  
  METHODS
  Clinical data of 82 de novo AML with t（8;21）who were newly diagnosed from Jan 2008 to Apr 2014 were analyzed retrospectively, 50 expressed CD56 and 32 not. Clinical characteristics and prognoses were compared between patients expressing and nonexpressing CD56.
  
  
  RESULTS
  There were no statistically significant differences in terms of age, gender, white blood cell count（WBC）, percentage of bone marrow blasts, extramedullary infiltration rate, the early mortality or the presence of additional cytogenetic abnormalities between CD56 + and CD56- groups（P＞0.05). The expressions of lymphatic antigens CD19 between CD56 + and CD56- groups showed significant difference （30.0% vs 53.1% , P=0.036). The complete remission and 3-year overall survival（OS）showed no significant differences between CD56+ and CD56-groups, while 3- year disease- free survival（DFS）showed significant differences（25.8% vs 46.9%, P=0.014). Multivariable analysis for DFS identified CD56 positivity as an independent predictor. DFS of who received allogeneic hematopoietic stem cell transplantation（HSCT）was better than those treated with intermediate- dose cytarabine/high dose cytarabine（IDAC）as postremission therapy.
  
  
  CONCLUSIONS
  The expression of CD56 in de-novo AML with t（8;21) appeared to be associated with poorer prognosis.
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Sha
authors.initials: S
authors.lastname: Liu
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Xudong
authors.initials: X
authors.lastname: Wei
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Ruihua
authors.initials: R
authors.lastname: Mi
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Ai
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Qingsong
authors.initials: Q
authors.lastname: Yin
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Xiaojiao
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Ruihua
authors.initials: R
authors.lastname: Fan
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Jieying
authors.initials: J
authors.lastname: Hu
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Xinghu
authors.initials: X
authors.lastname: Zhu
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Yuewen
authors.initials: Y
authors.lastname: Fu
authors.affiliation: Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
authors.forename: Yongping
authors.initials: Y
authors.lastname: Song
mesh_terms: D001853:Bone Marrow; D019002:CD56 Antigen; D002869:Chromosome Aberrations; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D003561:Cytarabine; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D019002:CD56 Antigen; C522918:NCAM1 protein, human; D003561:Cytarabine